TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›HOWL›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Werewolf Therapeutics, Inc. (HOWL) financials

Income statement

Werewolf Therapeutics, Inc. (HOWL) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$22.4M-$50.1M-$56.1M-$40.5M-$73.6M-$60.7M
Net income-$15.0M-$50.0M-$53.8M-$37.4M-$70.5M-$60.8M
EPS (diluted)-$28.08-$10.94-$1.86-$1.05-$1.63-$1.33

Cash flow

Werewolf Therapeutics, Inc. (HOWL) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$18.6M-$42.9M-$40.6M-$32.6M-$56.2M-$60.3M
Capital expenditures$560K$498K$3.61M$769K$254K$0.00
Free cash flow-$19.2M-$43.4M-$44.2M-$33.4M-$56.4M-$60.3M

Balance sheet

Werewolf Therapeutics, Inc. (HOWL) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$92.6M$158M$129M$134M$111M$57.0M
Total assets$96.4M$179M$160M$175M$127M$69.4M
Total liabilities$7.18M$26.5M$37.9M$63.5M$53.5M$44.6M
Long-term debt———$40.0M$32.1M$32.1M
Shareholders' equity-$51.9M$153M$122M$111M$73.4M$24.8M
Retained earnings-$51.9M-$253M-$307M-$344M-$415M-$475M
Shares (wtd avg diluted)1.00M18.5M28.9M35.6M43.9M46.8M

Every figure is extracted from Werewolf Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Werewolf Therapeutics, Inc.'s free cash flow?
-$60.3M in FY2025 (operating cash flow -$60.3M minus $0.00 of capital expenditures), from the SEC cash-flow statement.
Does HOWL pay a dividend?
Werewolf Therapeutics, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full HOWL analysis — verdict, score & filings →Is HOWL a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.